Please use this identifier to cite or link to this item:
|Title:||Clinical interventions for Takayasu arteritis: A systematic review|
|Authors:||Pacheco, Rafael L. [UNIFESP]|
Cruz Latorraca, Carolina de Oliveira [UNIFESP]
Silva de Souza, Alexandre Wagner [UNIFESP]
Pachito, Daniela V. [UNIFESP]
Riera, Rachel [UNIFESP]
|Citation:||International Journal Of Clinical Practice. Hoboken, v. 71, n. 11, p. -, 2017.|
|Abstract:||IntroductionTakayasu arteritis (TA) is a rare systemic vasculitis that affects large vessels often resistant to treatment and associated with high morbidity and mortality. Treatment is defied by the relapsing nature of the disease and frequent adverse effects of corticosteroids and immunosuppressors, rendering failure of treatment in a significant portion of patients. Considering the low quantity and quality of published studies focusing on treatment of TA, synthesis and critical assessment of the available evidence is fundamental to establish recommendations for clinical practice. ObjectiveTo evaluate the effectiveness and safety of clinical interventions for TA. MethodsSystematic review conducted in accordance to recommendations stated in the Cochrane Handbook, with inclusion of all comparative studies focusing on any type of clinical intervention for TA. ResultsFive comparative studies were included (one randomised clinical trial, two non-randomised clinical trials, and two historical cohorts) totalling 342 patients, aiming at the assessment of effectiveness of corticosteroids, immunosuppressors, biologics and other types of pharmacological treatment for distinct clinical presentations of TA. The quality of studies, assessed by the use of instruments developed specifically for each study design, was considered low. Data scarcity and clinical heterogeneity prevented quantitative synthesis (meta-analysis). ConclusionDespite an extensive literature search, few comparative studies with small sample sizes were retrieved. The quality of these studies was considered low, preventing recommendations on effectiveness and safety of the studied interventions for clinical practice. Until new comparative studies with more robust sample sizes are conducted, treatment of TA should be guided individually taking into account the severity of disease and the availability of treatment options.|
|Appears in Collections:||Artigo|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.